Brentuximab Vedotin
Extranodal Nasal NK/T Cell Lymphoma
Explore 50 assets in Extranodal Nasal NK/T Cell Lymphoma →Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Shanghai Zhongshan Hospital
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05316246CT.gov Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma | — | Unknown | — | — | — |
NCT02588651CT.gov A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) | — | Completed | — | — | — |
NCT01805037CT.gov Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Extranodal Nasal NK/T Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Brentuximab Vedotin (this asset) | Shanghai Zhongshan Hospital | P2 | B · 61 |
| Pegaspargase | CStone Pharmaceuticals | P4 | BBB |
| Dexasone | Mingzhi Zhang | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Centre, Singapore | P4 | BBB |
| Etoposide | Tarapeutics Science Inc. | P4 | BB |
| Tucidinostat | Ruijin Hospital | P4 | BB |
| Lenalidomide | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | P4 | BB |
| Asparaginase | National Cancer Centre, Singapore | P3 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BB |
+42 more in the Extranodal Nasal NK/T Cell Lymphoma cohort
Other indications for Brentuximab Vedotin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
| Anaplastic Large Cell Lymphoma | — | P3 | BBB · 72 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Brentuximab Vedotin in Extranodal Nasal NK/T Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/brentuximab-vedotin-extranodal-nasal-nkt-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →